Marcin Stobiecki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcin Stobiecki has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Danny M. Cohn
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
3 shared publications Emel Aygören‐Pürsün
Universitätsklinikum Frankfurt Frankfurt Germany
3 shared publicationsHenriette Farkas
Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology Semmelweis University Budapest Hungary
3 shared publications- Jonathan A. Bernstein
Division of Rheumatology, Allergy and Immunology University of Cincinnati College of Medicine Cincinnati Ohio USA
3 shared publications - Timothy Craig
Penn State University
3 shared publications Andrea Zanichelli
Department of Biomedical Sciences for Health University of Milan Milan Italy
2 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 6 (1)
A plain language summary of oral berotralstat for preventive treatment of hereditary angioedema attacks in children: early safety and efficacy results of the ongoing APeX-P study
(2026). A plain language summary of oral berotralstat for preventive treatment of hereditary angioedema attacks in children: early safety and efficacy results of the ongoing APeX-P study. Future Rare Diseases: Vol. 6, No. 1, 2701724.
- 6 August 2026
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 6 (1)
Open AccessA plain language summary of oral berotralstat for preventive treatment of hereditary angioedema attacks in children: early safety and efficacy results of the ongoing APeX-P study
(2026). A plain language summary of oral berotralstat for preventive treatment of hereditary angioedema attacks in children: early safety and efficacy results of the ongoing APeX-P study. Future Rare Diseases: Vol. 6, No. 1, 2701724.
- Open Access
- 4 March 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (3) , e70159
An International Delphi Study on Barriers to On‐Demand Treatment of Hereditary Angioedema Attacks
Background: Hereditary angioedema (HAE) is a rare inherited disorder characterized by unpredictable and potentially life‐threatening attacks of swelling. This international Delphi panel aimed to address questions related to on‐demand treatment of HAE attacks. Methods: A modified Delphi method was conducted with three rounds of surveys. Two non‐voting co‐chairs designed and managed the surveys, data collection, and analysis with a third‐party administrator. The international panel consisted of 19 expert HAE clinicians. Consensus was defined as ≥ 75% agreement with ≥ 75% of panelists voting. Results: The panel confirmed 24 statements across five key areas related to on‐demand treatment: defining “early” treatment, barriers to early administration, burden of treatment, tolerability and convenience, and patient–clinician interactions. Panelists defined early treatment as ≤ 60 min after onset of an HAE attack. Obstacles to early treatment include recognition of an HAE attack, and embarrassment/anxiety about administering parenteral treatment. Access to on‐demand treatment (i.e., carrying medication, cost, insurance coverage, regulatory approval) can be a burden for patients with HAE, and increasing access may improve adherence to guidelines. Logistical obstacles of parenteral administration that impact convenience, tolerability concerns (e.g., side effects), and cost of medication can all limit early use of on‐demand treatment. Additional options for on‐demand therapies beyond parenteral treatments could reduce some of the burdens. Panelists agreed that patient–physician shared decision‐making should be utilized. Conclusions: The Delphi consensus statements demonstrate the need for accessible and convenient on‐demand treatments for HAE attacks that will enable patients with HAE to improve adherence to guidelines.
- 4 March 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (3) , e70159
Open AccessAn International Delphi Study on Barriers to On‐Demand Treatment of Hereditary Angioedema Attacks
Background: Hereditary angioedema (HAE) is a rare inherited disorder characterized by unpredictable and potentially life‐threatening attacks of swelling. This international Delphi panel aimed to address questions related to on‐demand treatment of HAE attacks. Methods: A modified Delphi method was conducted with three rounds of surveys. Two non‐voting co‐chairs designed and managed the surveys, data collection, and analysis with a third‐party administrator. The international panel consisted of 19 expert HAE clinicians. Consensus was defined as ≥ 75% agreement with ≥ 75% of panelists voting. Results: The panel confirmed 24 statements across five key areas related to on‐demand treatment: defining “early” treatment, barriers to early administration, burden of treatment, tolerability and convenience, and patient–clinician interactions. Panelists defined early treatment as ≤ 60 min after onset of an HAE attack. Obstacles to early treatment include recognition of an HAE attack, and embarrassment/anxiety about administering parenteral treatment. Access to on‐demand treatment (i.e., carrying medication, cost, insurance coverage, regulatory approval) can be a burden for patients with HAE, and increasing access may improve adherence to guidelines. Logistical obstacles of parenteral administration that impact convenience, tolerability concerns (e.g., side effects), and cost of medication can all limit early use of on‐demand treatment. Additional options for on‐demand therapies beyond parenteral treatments could reduce some of the burdens. Panelists agreed that patient–physician shared decision‐making should be utilized. Conclusions: The Delphi consensus statements demonstrate the need for accessible and convenient on‐demand treatments for HAE attacks that will enable patients with HAE to improve adherence to guidelines.
- Open Access
- 18 November 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (11) , e70118
Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S
Background: Hereditary angioedema (HAE‐C1INH) attacks involving mucosal tissue may progress rapidly and often lead to substantial morbidity. Severe laryngeal attacks can be fatal without prompt administration of on‐demand treatment. This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2‐year, open‐label extension KONFIDENT‐S study (NCT05505916). Methods: Eligible participants ≥ 12 years with HAE‐C1INH self‐administered sebetralstat 600 mg film‐coated tablets with an optional second dose after 3 h, if warranted. Primary outcome: incidence of treatment‐emergent adverse events (TEAEs). Secondary outcomes: times to beginning of symptom relief, reduction in severity, and complete resolution. Results: At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat. Seven (43.8%) participants with laryngeal attacks experienced 14 TEAEs whereas 36 (35.3%) participants with abdominal attacks experienced 91 TEAEs. No difficulty swallowing sebetralstat was reported. Median (IQR) time to treatment: 11.5 min (1.0–34.0) and 20.0 min (1.0–61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76–3.02) and 1.27 h (0.76–3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24). Most mucosal attacks that achieved beginning of symptom relief within 12 h did so with a single dose of sebetralstat (laryngeal: 96.0%; abdominal: 95.8%). Conventional on‐demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks. Conclusion: Oral sebetralstat enabled rapid treatment of laryngeal and abdominal attacks of all severities, was well tolerated, and provided early symptom relief.
- 18 November 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (11) , e70118
Open AccessSebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S
Background: Hereditary angioedema (HAE‐C1INH) attacks involving mucosal tissue may progress rapidly and often lead to substantial morbidity. Severe laryngeal attacks can be fatal without prompt administration of on‐demand treatment. This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2‐year, open‐label extension KONFIDENT‐S study (NCT05505916). Methods: Eligible participants ≥ 12 years with HAE‐C1INH self‐administered sebetralstat 600 mg film‐coated tablets with an optional second dose after 3 h, if warranted. Primary outcome: incidence of treatment‐emergent adverse events (TEAEs). Secondary outcomes: times to beginning of symptom relief, reduction in severity, and complete resolution. Results: At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat. Seven (43.8%) participants with laryngeal attacks experienced 14 TEAEs whereas 36 (35.3%) participants with abdominal attacks experienced 91 TEAEs. No difficulty swallowing sebetralstat was reported. Median (IQR) time to treatment: 11.5 min (1.0–34.0) and 20.0 min (1.0–61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76–3.02) and 1.27 h (0.76–3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24). Most mucosal attacks that achieved beginning of symptom relief within 12 h did so with a single dose of sebetralstat (laryngeal: 96.0%; abdominal: 95.8%). Conventional on‐demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks. Conclusion: Oral sebetralstat enabled rapid treatment of laryngeal and abdominal attacks of all severities, was well tolerated, and provided early symptom relief.
- Open Access
- 29 August 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (11) , 3094-3103.e5
Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
- 29 August 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (11) , 3094-3103.e5
Open AccessLong-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
- Open Access
- 28 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3152
Venom Immunotherapy Does Not Affect Survival of Patients with Malignant Tumor in Poland
Background: Allergen immunotherapy (AIT) is a well-established and efficient method of causative treatment for allergic rhinitis, asthma and insect venom allergy. Traditionally, a recent history of malignant neoplasm is regarded as a contraindication to AIT due to concerns that AIT might stimulate tumor growth. However, there are no data confirming that the silencing of the Th2 response affects prognosis in cancer. Objectives: The aim of this study was to investigate frequency of malignant tumors in patients undergoing AIT and the association between AIT and cancer-related mortality. Patients and Methods: A group of 2577 patients with insect venom allergy undergoing AIT in 10 Polish allergology centers was screened in the Polish National Cancer Registry. Data on cancer type, diagnosis time and patients’ survival were collected and compared with the general population. Results: In the study group, 86 cases of malignancies were found in 85 patients (3.3% of the group). The most common were breast (19 cases), lung (9 cases), skin (8 cases), colon and prostate cancers (5 cases each). There were 21 cases diagnosed before AIT, 38 during and 27 after completing AIT. Laplace’s crude incidence rate was 159.5/100,000/year (general population rate: 260/100,000/year). During follow-up, 13 deaths related to cancer were revealed (15% of patients with cancer). Laplace’s cancer mortality rate was 37.3/100,000/year (general population rate: 136.8/100,000/year). Conclusions: Malignancy was found in patients undergoing immunotherapy less often than in the general population. Patients with cancer diagnosed during or after AIT did not show a lower survival rate, which suggests that AIT does not affect the prognosis.
- 28 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3152
Open AccessVenom Immunotherapy Does Not Affect Survival of Patients with Malignant Tumor in Poland
Background: Allergen immunotherapy (AIT) is a well-established and efficient method of causative treatment for allergic rhinitis, asthma and insect venom allergy. Traditionally, a recent history of malignant neoplasm is regarded as a contraindication to AIT due to concerns that AIT might stimulate tumor growth. However, there are no data confirming that the silencing of the Th2 response affects prognosis in cancer. Objectives: The aim of this study was to investigate frequency of malignant tumors in patients undergoing AIT and the association between AIT and cancer-related mortality. Patients and Methods: A group of 2577 patients with insect venom allergy undergoing AIT in 10 Polish allergology centers was screened in the Polish National Cancer Registry. Data on cancer type, diagnosis time and patients’ survival were collected and compared with the general population. Results: In the study group, 86 cases of malignancies were found in 85 patients (3.3% of the group). The most common were breast (19 cases), lung (9 cases), skin (8 cases), colon and prostate cancers (5 cases each). There were 21 cases diagnosed before AIT, 38 during and 27 after completing AIT. Laplace’s crude incidence rate was 159.5/100,000/year (general population rate: 260/100,000/year). During follow-up, 13 deaths related to cancer were revealed (15% of patients with cancer). Laplace’s cancer mortality rate was 37.3/100,000/year (general population rate: 136.8/100,000/year). Conclusions: Malignancy was found in patients undergoing immunotherapy less often than in the general population. Patients with cancer diagnosed during or after AIT did not show a lower survival rate, which suggests that AIT does not affect the prognosis.
- Open Access
- 29 December 2023
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 19 (4) , 334-342
Lanadelumab demonstrates high efficacy in reducing the frequency of angioedema attacks in patients with severe HAE in real-life settings
Warunkach codziennej praktyki klinicznej
- 29 December 2023
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 19 (4) , 334-342
Open AccessLanadelumab demonstrates high efficacy in reducing the frequency of angioedema attacks in patients with severe HAE in real-life settings
Warunkach codziennej praktyki klinicznej
- Open Access
- 18 June 2021
- Published by Wiley in Clinical and Translational Allergy
- Vol. 11 (4) , e12035
Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
Background: Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). The objective of this report is to summarize results from an interim analysis of an ongoing long‐term safety study of berotralstat in patients with HAE.Methods: APeX‐S is an ongoing, phase 2, open‐label study conducted in 22 countries (ClinicalTrials.gov, NCT03472040). Eligible patients with a clinical diagnosis of HAE due to C1 inhibitor deficiency (HAE‐C1‐INH) were centrally allocated to receive berotralstat 150 or 110 mg once daily. The primary objective was to determine long‐term safety and the secondary objective was to evaluate effectiveness.Results: Enrolled patients (N = 227) received berotralstat 150 mg (n = 127) or 110 mg (n = 100) once daily. The median (range) duration of exposure was 342 (11–540) and 307 (14–429) days for the 150‐mg and 110‐mg groups, respectively. Treatment‐emergent adverse events (TEAEs) occurred in 91% (n = 206) of patients. The most common TEAEs across treatment groups were upper respiratory tract infection (n = 91, 40%), abdominal pain (n = 57, 25%), headache (n = 40, 18%), and diarrhea (n = 31, 14%) and were mostly mild to moderate. Fifty percent (n = 113) of patients had at least one drug‐related adverse event (AE; 150 mg, n = 57 [45%]; 110 mg, n = 56 [56%]), and discontinuations due to AEs occurred in 19 (8%) patients (150 mg, n = 13 [10%]; 110 mg, n = 6 [6%]). Three (1.3%) patients experienced a drug‐related serious TEAE. Among patients who received berotralstat through 48 weeks (150 mg, n = 73; 110 mg, n = 30), median HAE attack rates were low in month 1 (150 mg, 1.0 attacks/month; 110 mg, 0.5 attacks/month) and remained low through 12 months (0 attacks/month in both dose groups). Mean HAE attack rates followed a similar trend, and no evidence for patient tolerance to berotralstat emerged. In both dose groups, angioedema quality of life scores showed clinically meaningful changes from baseline.Conclusions: In this analysis, both berotralstat doses, 150 and 110 mg once daily, were generally well tolerated. Effectiveness results support the durability and robustness of berotralstat as prophylactic therapy in patients with HAE.Trial registration: The study is registered with ClinicalTrials.gov (NCT03472040).
- 18 June 2021
- Published by Wiley in Clinical and Translational Allergy
- Vol. 11 (4) , e12035
Open AccessLong‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
Background: Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). The objective of this report is to summarize results from an interim analysis of an ongoing long‐term safety study of berotralstat in patients with HAE.Methods: APeX‐S is an ongoing, phase 2, open‐label study conducted in 22 countries (ClinicalTrials.gov, NCT03472040). Eligible patients with a clinical diagnosis of HAE due to C1 inhibitor deficiency (HAE‐C1‐INH) were centrally allocated to receive berotralstat 150 or 110 mg once daily. The primary objective was to determine long‐term safety and the secondary objective was to evaluate effectiveness.Results: Enrolled patients (N = 227) received berotralstat 150 mg (n = 127) or 110 mg (n = 100) once daily. The median (range) duration of exposure was 342 (11–540) and 307 (14–429) days for the 150‐mg and 110‐mg groups, respectively. Treatment‐emergent adverse events (TEAEs) occurred in 91% (n = 206) of patients. The most common TEAEs across treatment groups were upper respiratory tract infection (n = 91, 40%), abdominal pain (n = 57, 25%), headache (n = 40, 18%), and diarrhea (n = 31, 14%) and were mostly mild to moderate. Fifty percent (n = 113) of patients had at least one drug‐related adverse event (AE; 150 mg, n = 57 [45%]; 110 mg, n = 56 [56%]), and discontinuations due to AEs occurred in 19 (8%) patients (150 mg, n = 13 [10%]; 110 mg, n = 6 [6%]). Three (1.3%) patients experienced a drug‐related serious TEAE. Among patients who received berotralstat through 48 weeks (150 mg, n = 73; 110 mg, n = 30), median HAE attack rates were low in month 1 (150 mg, 1.0 attacks/month; 110 mg, 0.5 attacks/month) and remained low through 12 months (0 attacks/month in both dose groups). Mean HAE attack rates followed a similar trend, and no evidence for patient tolerance to berotralstat emerged. In both dose groups, angioedema quality of life scores showed clinically meaningful changes from baseline.Conclusions: In this analysis, both berotralstat doses, 150 and 110 mg once daily, were generally well tolerated. Effectiveness results support the durability and robustness of berotralstat as prophylactic therapy in patients with HAE.Trial registration: The study is registered with ClinicalTrials.gov (NCT03472040).
- Open Access
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 36 (3) , 346-353
Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit
Introduction Venom immunotherapy treatment (VIT) is the only causal treatment of hymenoptera venom anaphylaxis, which aims to provide long-lasting immunoprotection against severe reactions to subsequent stings. Aim To reassess the compliance of VIT procedures in the Polish allergy centres...
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 36 (3) , 346-353
Open AccessVenom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit
Introduction Venom immunotherapy treatment (VIT) is the only causal treatment of hymenoptera venom anaphylaxis, which aims to provide long-lasting immunoprotection against severe reactions to subsequent stings. Aim To reassess the compliance of VIT procedures in the Polish allergy centres...
- 1 March 2017
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 118 (3) , 326-332
Simplification of intradermal skin testing in Hymenoptera venom allergic children
- 1 March 2017
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 118 (3) , 326-332
Simplification of intradermal skin testing in Hymenoptera venom allergic children